GLP-1 Myths, Tested Against the Evidence

Five claims about GLP-1 medicines circulate in Indian family WhatsApp groups, gym conversations and comment sections: that using them is cheating, that you can never come off them, that they wreck your metabolism, that they are nothing but appetite suppression, and that they burn muscle. Two of those five are partly right, and a page that resolved all five in the medicine's favour would not be worth reading. This article takes each claim to the primary evidence and reports where it holds, where it distorts something real, and where the evidence has not settled the question at all.

Key Takeaways:

• Weight loss by any route produces persistent hormonal changes that increase hunger and reduce energy expenditure. The medicine acts on biology that is already there. That biology is not evidence of cheating.
• WHO's December 2025 guideline positions GLP-1 medicines as long-term tools for a chronic condition. No authority has written a stopping rule, and none has mandated indefinite treatment. Both halves of that matter.
• A 12-week crossover trial found semaglutide reduced energy intake by about 24% but did not change resting metabolic rate adjusted for lean mass against placebo. Drug-specific metabolic damage is not established on current evidence.
• GLP-1 receptors appear in the pancreas, gastrointestinal tract, kidneys, heart and immune cells. The cardiovascular and renal effects follow from that distribution.
• Lean-mass loss and weight regain after stopping are both real and narrower than the versions that circulate. Both belong in a clinical conversation rather than a comment thread.

In Indian conversations this usually arrives as some version of pen se wazan kam karna cheating hai, or the flatter English form, that real weight loss should come only from diet and exercise.

The classification argument runs against it. The World Health Organization treats obesity as a chronic, complex, relapsing disease requiring long-term care rather than an episode of poor discipline, and the Endocrine Society of India and Indian consensus groups describe it the same way, as a chronic relapsing disease of excess adiposity that impairs health. Indian guidance also sets the threshold lower than Western practice, with obesity recognised from around a BMI of 25 kg/m² in Asian Indians, because cardiometabolic risk appears at lower weights in this population.

The physiology argument is the stronger one, because it applies to people who have never touched a medicine. When weight is lost voluntarily, the body defends the weight it has lost. A New England Journal of Medicine study of diet-induced weight loss of around 13.5 kg found persistent hormonal changes for at least a year afterwards: leptin and other satiety hormones stayed down, ghrelin stayed up, and subjective hunger was higher than before the diet. Alongside that, review work on adaptive thermogenesis reports that maintaining a weight reduction of 10% or more comes with a fall in 24-hour energy expenditure of roughly 20 to 25%, around 300 to 400 fewer kcal a day than a never-obese person of the same size, and larger than body composition alone would predict.

So there is a grain of truth in the objection. These medicines do act on biology rather than on resolve, and in that narrow sense the loss is not "pure effort". The distortion is the moral frame built on top of it. Less energy burned and more hunger is what happens after weight loss by any route. The biology is there whether or not anyone takes a medicine.

No health authority has written down that these medicines are for life, and none has written down when to stop either. Both halves of that matter.

WHO's December 2025 global guideline on GLP-1 therapies states that GLP-1 receptor agonists and dual GIP/GLP-1 agonists may be used as long-term treatment for obesity in adults, positioning them inside chronic care for a chronic disease. That recommendation is explicitly conditional, and WHO says why: long-term efficacy, safety, maintenance and discontinuation data all remain limited, and cost and health-system readiness vary. Product labelling for semaglutide and tirzepatide does not specify indefinite therapy either. There is no fixed stopping rule anywhere in the guidance, and the absence is the finding rather than an oversight.

What drives the myth is what trials show happens after treatment stops, which is substantial weight regain. The distortion is the leap from "regain is common after stopping" to "you are locked in". Guidance says obesity is chronic and these are long-term tools within that. It does not say everyone must take them indefinitely, and it does not yet define the best duration or the best way to come off.

Two separate questions sit inside this claim, and the argument only works if you keep them apart. The first is what weight loss itself does to resting energy expenditure. The second is whether GLP-1-mediated loss reduces it by more than an equivalent diet-induced loss would, which is the only version that would count as harm from the medicine.

On the first question, the answer is that energy expenditure falls, and falls further than the change in fat and lean mass alone predicts. That is adaptive thermogenesis, and it has been documented repeatedly in diet-only and exercise-only weight loss. In one mixed-methods trial in women with severe obesity, weight loss of about 13.8 kg through total diet replacement was accompanied by a fall in resting energy expenditure of roughly 291 kcal a day, of which about 150 kcal a day was attributed to adaptive thermogenesis. No medicine was involved.

On the second question, the drug-specific data are limited but do not point to extra damage. A 12-week randomised crossover trial in adults with obesity using semaglutide 1.0 mg weekly measured resting metabolic rate adjusted for lean body mass after dose escalation. Energy intake fell by about 24% and body weight by 5.0 kg, mostly from fat mass, but resting metabolic rate adjusted for lean mass did not differ between semaglutide and placebo. This trial reports a single analysis rather than separate treatment-regimen and efficacy estimands, so the 5.0 kg figure should be read as the crossover result at that dose and duration and nothing wider. In SEMALEAN, an observational cohort of 115 adults with obesity followed on semaglutide for 12 months, resting energy expenditure fell by month 7, around 244 kcal per 24 hours below baseline, and then rose again by month 12, with expenditure normalised to lean mass increasing significantly over that second period.

The honest position is that trials directly comparing energy expenditure between drug-mediated loss and matched non-drug loss, with full indirect calorimetry, are scarce. On what exists, adaptive thermogenesis looks like a feature of weight loss rather than a signature of these medicines. Whether the slowdown reverses after treatment ends is a different question again, and one where the evidence is thinner still.

Appetite is central, and the trial data say so plainly. The same 12-week crossover found that semaglutide cut total daily energy intake by roughly a quarter, shifted food preference away from high-fat energy-dense foods, and worked through less hunger, fewer cravings and better control of eating rather than through any change in resting metabolic rate.

The claim goes wrong at the word "just". Across that distribution, GLP-1 receptor agonists enhance glucose-dependent insulin secretion and reduce glucagon, slow gastric emptying through effects on smooth muscle and vagal afferents, and modulate lipids and blood pressure. Cardiovascular outcome trials in the populations they enrolled have reported reductions in major adverse cardiovascular events and cardiorenal protection that were not explained by HbA1c or weight change alone, and reviews describe anti-inflammatory effects including falls in markers such as hs-CRP.

None of that is written here as a reason for anyone to take one. It is written because the same wide receptor distribution that produces effects beyond appetite is also why the adverse-effect profile is not confined to the stomach. A multi-system drug is multi-system in both directions, and which direction matters for a given person is a clinical judgement, not a general fact.

Lean-mass loss is real. Any substantial weight loss, by diet, by surgery or by medicine, takes some lean tissue with it, and pretending otherwise would be the fastest way to lose a reader who has watched their own body-composition report. The question the myth is actually asking is whether these medicines take more than comparable routes do.

Comparative analyses so far suggest lean-mass loss with GLP-1-mediated weight loss sits broadly in line with other aggressive weight-loss methods, and that the proportion of the body made up of lean mass often rises rather than falls, because fat mass falls further. The SEMALEAN cohort, which paired DXA with functional testing over 12 months, found that lean mass did decrease, but that participants around 50 years old typically showed improved muscle function and lower rates of sarcopenia. Some individuals in that cohort did develop sarcopenia. Because the study had no non-drug control group, it could not attribute that to the medicine, to the weight loss, or to something else.

What has not been settled is whether these medicines are better or worse than bariatric surgery or very-low-calorie diets for muscle quantity and function over years, particularly in older adults, in people with sarcopenic obesity, and in South Asians, who start with lower lean mass and higher central adiposity at any given BMI. Data in Indian populations and in adults over 60 are especially thin.

The five claims above are the ones people argue about. They are not the ones the labelling warns about, which is worth noticing on its own.

US labelling for semaglutide and other GLP-1 receptor agonists carries a boxed warning about thyroid C-cell tumours seen in rodents. Human data so far have not shown a clear increase in medullary thyroid carcinoma, but because that uncertainty has not been closed, these medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia type 2. Acute pancreatitis has been observed with GLP-1 receptor agonists and with tirzepatide, and severe persistent abdominal pain radiating to the back is treated as an emergency signal rather than a side effect to wait out. An increased occurrence of gallbladder disease has also been reported, likely related in part to rapid weight loss.

Two of these claims survive contact with the evidence in modified form. Lean-mass loss happens. Weight regain after stopping happens. The other three describe something that either applies to weight loss generally rather than to the medicine, or misstates what guidance says, or shrinks a drug with receptors in half a dozen organ systems down to an appetite switch. The pattern worth taking away is that the arguments people have about these medicines and the cautions written on their labels are almost entirely different lists. Anything that follows from either belongs in a conversation with a registered medical practitioner who knows your history, not in a comment thread.

Questions about whether a GLP-1 medicine is appropriate for your specific situation? A Voy clinician can review your history and give you a direct answer. Book a consultation.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.